

Risk Factors & Cardiovascular Disease

Bibliography of One Hundred Key Papers

selected by **Guy G. De Backer, MD, PhD**

Department of Public Health - Ghent University - and Department of Cardiac Rehabilitation
University Hospital - Ghent - BELGIUM - e-mail: guy.debacker@ugent.be

-
- Abbott R, Wilson PW, Kannel WB, et al.** *High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis.* 1988;8:207-211.
-
- Anderson K, Wilson PW, Odell PM, et al.** *An updated coronary risk profile. A statement for health professionals. Circulation.* 1991;83:356-362.
-
- Andersson O, Almgren T, Persson B, et al.** *Survival in treated hypertension: follow up study after two decades. BMJ.* 1998;317:167-171.
-
- Asia Pacific Cohort Studies Collaboration.** *Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol.* 2005;34:1036-1045.
-
- Barr ELM, Zimmet PZ, Welborn TA, et al.** *Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose and impaired glucose tolerance. Circulation.* 2007;116:151-157.
-
- Bartecchi CE, MacKenzie TD, Schrier RW.** *The human costs of tobacco use (I). N Engl J Med.* 1994;330:907-912.
-
- Batty GD.** *Physical activity and coronary heart disease in older adults. A systematic review of epidemiological studies. Eur J Public Health.* 2002;12:171-176.
-
- Becker A, Bos G, de Vegt F, et al.** *Cardiovascular events in type 2 diabetes: comparison with non-diabetic individuals without and with prior cardiovascular disease. 10-Year follow-up of the Hoorn Study. Eur Heart J.* 2003;24:1406-1413.
-
- Benetos A, Rudnichi A, Thomas F, et al.** *Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension.* 1999;33:44-52.
-
- Benetos A, Zureik M, Morcet J, et al.** *A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol.* 2000;35:673-680.
-
- Beulens JWJ, de Bruijne LM, Stolk RP, et al.** *High dietary glycaemic load and glycaemic index increase risk of cardiovascular disease among middle-aged women. J Am Coll Cardiol.* 2007;50:14-21.
-

Bibliography of One Hundred Key Papers

- Blankenberg S, Luc G, Ducimetiere P, et al.** *PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME).* **Circulation.** 2003;108:2453-2459.
-
- British Heart Foundation Statistics Database.** *Coronary heart disease statistics 2007.* **www.heartstats.org.** Accessed 15 June 2008.
-
- Casas J, Shah T, Cooper J, et al.** *Insight into the nature of the CRP–coronary event association using Mendelian randomization.* **Int J Epidemiol.** 2006;35:922-931.
-
- Clifton P, Keogh JB, Foster PR, et al.** *Effect of weight loss on inflammatory and endothelial markers and FMD using two low-fat diets.* **Int J Obes.** 2005;29:1445-1451.
-
- Conroy R, Pyorala K, Fitzgerald AP, et al.** *Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.* **Eur Heart J.** 2003;24:987-1003.
-
- Cuspidi C, Ambrosioni E, Mancia G, et al.** *Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey.* **J Hypertens.** 2002;20:1307-1314.
-
- Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease.** *Meta-analysis of prospective studies.* **Circulation.** 2000;102:1082-1085.
-
- Danesh J, Wheeler JG, Hirschfield GM, et al.** *C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.* **N Engl J Med.** 2004;350:1387-1397.
-
- Davey Smith G, Lawlor DA, Timpson N.** *C-reactive protein and cardiovascular risk: still an unknown quantity?* **Ann Intern Med.** 2006;145:70-72.
-
- De Bacquer D, De Backer G, Ostor E, et al; EUROASPIRE I Study Group.** *Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort.* **Eur J Cardiovasc Prev Rehabil.** 2003;10:289-295.
-
- De Koning L, Merchant AT, Pogue J, et al.** *Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies.* **Eur Heart J.** 2007;28:850-856.
-
- De Sutter J, De Bacquer D, Cuypers S, et al.** *Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary events in men at work: a report from the BELSTRESS study.* **Eur Heart J.** 2005;26:2644-2649.
-
- DECODE Study Group; European Diabetes Epidemiology Group.** *Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 hour diagnostic criteria.* **Arch Intern Med.** 2001;161:397-405.
-
- Dyer A, Persky V, Stamler J, et al.** *Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies.* **Am J Epidemiol.** 1980;112:736-749.
-



-
- EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events.** *Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries.*
Lancet. 2001;357:995-1001.
-
- Ezzati M, Lopez AD, Rodgers A, et al.** *Selected major risk factors and global and regional burden of disease.*
Lancet. 2002;360:1347-1360.
-
- Flipovsky J, Ducimetiere P, Safar M.** *Prognostic significance of exercise heart rate and blood pressure in middle-aged men.*
Hypertension. 1992;20:333-339.
-
- Folsom A, Kushi LH, Anderson KE, et al.** *Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study.*
Arch Intern Med. 2000;160:2117-2128.
-
- Ford E.** *Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence.*
Diabetes Care. 2005;28:1769-1778.
-
- Fourth Joint Task Force of the European Society of Cardiology and other societies on CVD Prevention in Clinical Practice.** *European guidelines on CVD prevention in clinical practice: full document.*
Eur J Cardiovasc Prev Rehab. 2007;14(suppl 2):S1-S113.
-
- Franklin S, Larson MG, Khan SA, et al.** *Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.*
Circulation. 2001;103:1245-1249.
-
- Gami AS, Witt BJ, Howard DE, et al.** *Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies.*
J Am Coll Cardiol. 2007;49:403-414.
-
- Geelen A, Brouwer IA, Schouten EG, et al.** *Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans.*
Am J Clin Nutr. 2005;81:416-420.
-
- Gillum R, Makuc D, Feldman J.** *Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study.*
Am Heart J. 1991;121:172-177.
-
- Greenland P, Daviglius M, Dyer A.** *Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry.*
Am J Epidemiol. 1999;149:853-862.
-
- Grundy S.** *Prevention of atherosclerotic cardiovascular disease: why are the benefits of lifestyle therapies neglected?*
Dialogues Cardiovasc Med. 2005;10:73-88.
-
- Hackam D, Anand SS.** *Emerging risk factors for atherosclerotic vascular disease. A critical review of the evidence.*
JAMA. 2003;290:932-940.
-
- Haffner S, Lehto S, Ronnemara T, et al.** *Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction.*
N Engl J Med. 1998;339:229-234.
-

Bibliography of One Hundred Key Papers

- Hill AB.** *Principles of Medical Statistics.* (Sir Austin Bradford Hill).
1st edition, *The Lancet*, 1937;
12th edition, *Oxford University Press*, 1991.
-
- Homocysteine Studies Collaboration.** *Homocysteine and risk of ischaemic heart disease and stroke: a meta-analysis.*
JAMA. 2002;288:2015-2022.
-
- Hozawa A, Folsom AR, Sharrett AR, et al.** *Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors: comparison of African American with white subjects: Atherosclerosis Risk in Communities Study.*
Arch Intern Med. 2007;167:573-579.
-
- Hu G, Jousilahti P, Qiao Q, et al.** *The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease.*
J Am Coll Cardiol. 2005;45:1413-1418.
-
- Hu G, Tuomilehto J, Borodulin K, et al.** *The joint associations of occupational, commuting and leisure-time physical activity and the Framingham risk score on the 10-year risk of coronary heart disease.*
Eur Heart J. 2007;28:492-498.
-
- Jeppesen J, Hein HO, Suadicani P, et al.** *Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.*
Circulation. 1998;97:1029-1036.
-
- Jouven X, Desnos M, Guerot C.** *Predicting sudden death in the population: the Paris Prospective Study.*
Circulation. 1996;99:1978-1983.
-
- Juutilainen A, Lehto S, Rönnemaa T, et al.** *Type 2 Diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects.*
Diabetes Care. 2005;28:2901-2907.
-
- Kannel W.** *Blood pressure as a cardiovascular risk factor: prevention and treatment.*
JAMA. 1996;275:1571-1576.
-
- Kannel W, Kannel C, Paffenbarger RS, et al.** *Heart rate and cardiovascular mortality: the Framingham study.*
Am Heart J. 1987;113:1489-1494.
-
- Khaw K, Wareham N, Luben R, et al.** *Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk).*
BMJ. 2001;322:15B-18B.
-
- Kristal-Boneh E, Silber H, Harari G, et al.** *The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS study).*
Eur Heart J. 2000;21:116-124.
-
- Kushner I, Sehgal AR.** *Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk?*
Arch Intern Med. 2002;162:867-869.
-



-
- Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L.** *Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.* **BMJ.** 1984;289:1257-1261.
-
- Larsson B, Svardsudd K, Welin L, et al.** *Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.* **BMJ.** 1984;288:1401-1411.
-
- Law MR, Morris JK, Wald NJ.** *Environmental tobacco smoke exposure and ischemic heart disease: an evaluation of the evidence.* **BMJ.** 1997;315:973-980.
-
- Lee C, Folsom AR, Pankow JS, et al; Atherosclerosis Risk in Communities (ARIC) Study Investigators.** *Cardiovascular events in diabetic and non-diabetic adults with or without history of myocardial infarction.* **Circulation.** 2004;109:855-860.
-
- Lewington S, Clarke R, Qizilbash N, et al.** *Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration.* **Lancet.** 2002;360:1903-1913.
-
- Libby P, Ridker PM, Maseri A.** *Inflammation and atherosclerosis.* **Circulation.** 2002;105:1135-1143.
-
- Lloyd-Jones DM, Leip EP, Larson MG, et al.** *Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.* **Circulation.** 2006;113:791-798.
-
- Lowe G.** *Dental disease, coronary heart disease and stroke, and inflammatory markers: what are the associations and what do they mean?* **Circulation.** 2004;109:1076-1078.
-
- Lowe G.** *Circulating inflammatory markers and risks of cardiovascular and noncardiovascular disease.* **J Thromb Haemost.** 2005;3:1618-1627.
-
- Lowe G.** *Can haematological tests predict cardiovascular risk? The 2005 Kettle lecture.* **Br J Haematol.** 2006;133:232-250.
-
- MacKenzie TD, Bartecchi CE, Schrier RW.** *The human costs of tobacco use (2).* **N Engl J Med.** 1994;330:975-980.
-
- MacMahon S, Peto R, Cutler J, et al.** *Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.* **Lancet.** 1990;335:765-774.
-
- Meisinger C, Loewel H, Mraz W, et al.** *Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: result from the MONICA/KORA Augsburg cohort study.* **Eur Heart J.** 2005;26:271-278.
-

Bibliography of One Hundred Key Papers

- National Institutes of Health.** *Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report.*
Obes Res. 1998;6:51S-209S.
-
- Neaton J, Blackburn H, Jacobs D, et al; Multiple Risk Factor Intervention Trial Research Group.** *Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial.*
Arch Intern Med. 1992;152:1490-1500.
-
- Neaton J, Wentworth D.** *Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group.*
Arch Intern Med. 1992;152:56-64.
-
- Oguma Y, Shinoda-Tagawa T.** *Physical activity decreases cardiovascular disease risk in women: review and meta-analysis.*
Am J Prev Med. 2004;26:407-418.
-
- Olsen MH, Hansen TW, Christensen MK, et al.** *N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.*
Eur Heart J. 2007;28:1374-1381.
-
- Pajunen P, Koukkunen H, Ketonen M, et al.** *Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FIMAMI study.*
Diabetologia. 2005;48:2519-2524.
-
- Panagiotakos D, Pitsavos C, Chrysohoou C, et al.** *The associations between leisure-time physical activity and inflammatory and coagulation markers related to cardiovascular disease: the ATTICA Study.*
Prev Med. 2005;40:432-437.
-
- Pearson T, Mensah GA, Alexander RW, et al.** *Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.*
Circulation. 2003;107:499-551.
-
- Pischon T, Hankinson SE, Hotamisligil GS, et al.** *Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women.*
Circulation. 2003;108:155-160.
-
- Prescott E, Hippe L, Schnohr P, et al.** *Smoking and risk of myocardial infarction in women and men: longitudinal population study.*
BMJ. 1998;316:1043-1047.
-
- Primatesta P, Brookes M, Poulter NR.** *Improved hypertension management and control. Results from the Health Survey for England 1998.*
Hypertension. 2001;38:827-832.
-
- Pyyrälä K, Qiao Q, Gao WG, et al; DECODE Study Group.** *Metabolic syndrome in non-diabetic Europeans: relation to cardiovascular mortality.*
Atherosclerosis. 2006;7:154.
-
- Reunanen A, Karjalainen J, Ristola P, et al.** *Heart rate and mortality.*
J Intern Med. 2000;247:231-239.
-



-
- Ridker P.** *C-reactive protein and the prediction of cardiovascular events among those at intermediate risk.*
J Am Coll Cardiol. 2007;49:2129-2238.
-
- Ridker P, Hennekens CH, Buring JE, et al.** *C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.*
N Engl J Med. 2000;342:836-843.
-
- Ridker P, Rifai N, Rose L, et al.** *Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.*
N Engl J Med. 2002;347:1557-1565.
-
- Rose G.** *Sick individuals and sick populations.*
Int J Epidemiol. 1985;14:32-38.
-
- Ross R.** *Atherosclerosis: an inflammatory disease.*
N Engl J Med. 1999;340:115-126.
-
- Rozanski A, Blumenthal JA, Davidson KW, et al.** *The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioural cardiology.*
J Am Coll Cardiol. 2005;45:637-651.
-
- Sanders Williams R.** *The genetics of cardiovascular disease: from genotype to phenotype.*
Dialogues Cardiovasc Med. 2004;9:3-22.
-
- Scarabin P, Arveiler D, Amouyel P, et al.** *Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME Study.*
Atherosclerosis. 2003;166:103-109.
-
- Scottish Intercollegiate Guidelines Network.** *Risk estimation and the prevention of cardiovascular disease. A national clinical guideline.*
February 2007. www.sign.ac.uk. Accessed 15 June 2008.
-
- Seccareccia F, Pannozzo F, Dima F, et al.** *Heart rate as a predictor of mortality: the MATISS project.*
Am J Public Health. 2001;91:1258-1263.
-
- Shaper A, Wannamethee G, Macfarlane P, et al.** *Heart rate, ischemic heart disease and sudden death in middle-aged British men.*
Br Heart J. 1993;70:49-55.
-
- Smith A, Patterson C, Yarnell J, et al.** *Which haemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study.*
Circulation. 2005;112:3080-3087.
-
- Stephoe A, Marmot M.** *The role of psychobiological pathways in socioeconomic inequalities in cardiovascular disease risk.*
Eur Heart J. 2002;23:13-25.
-
- St-Pierre A, Cantin B, Bergeron J, et al.** *Inflammatory markers and long-term risk of ischemic heart disease in men. A 13-year follow-up of the Quebec Cardiovascular Study.*
Atherosclerosis. 2005;182:315-321.
-

Bibliography of One Hundred Key Papers

- Task force on Diabetes and CVD of the ESC and the EASD.** *Guidelines on diabetes, pre-diabetes and CVD: full text.*
Eur Heart J. 2007(suppl C):C3-C74.
-
- Thompson PD.** *Exercise and the heart: the Good, the Bad and the Ugly.*
Dialogues Cardiovasc Med. 2002;7:143-164.
-
- Timpson N, Lawlor DA, Harbord R, et al.** *C-reactive protein and its role in metabolic syndrome: mendelian randomisation study.*
Lancet. 2005;366:1954-1959.
-
- Vaccaro O, Eberly L, Neaton J, et al.** *Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.*
Arch Intern Med. 2004;164:1438-1443.
-
- Van Biesen W, De Bacquer D, Verbeke F, et al.** *The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years.*
Eur Heart J. 2007;28:478-483.
-
- Vasan R, Larson MG, Leip EP, et al.** *Impact of high-normal blood pressure on the risk of cardiovascular disease.*
N Engl J Med. 2001;345:1291-1297.
-
- Volpato S, Pahor M, Ferrucci L, et al.** *Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults. The Health, Aging, and Body Composition Study.*
Circulation. 2004;109:607-612.
-
- Walldius G, Jungner I, Holme I, et al.** *High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.*
Lancet. 2001;358:2026-2033.
-
- Wang J, Ruotsalainen S, Moilanen L, et al.** *The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly Finns.*
Eur Heart J. 2007;28:857-864.
-
- Whiteley L, Padamanabhan S, Hole D, et al.** *Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey.*
Diabetes Care. 2005;28:1588-1593.
-
- Wilhelmsen L.** *Coronary heart disease: epidemiology of smoking and intervention studies of smoking.*
Am Heart J. 1988;115(1 pt 2):242-249.
-
- Wilson K, Gibson N, Willan A, et al.** *Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies.*
Arch Intern Med. 2000;160:939-944.
-
- Wilson P.** *CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper.*
Circulation. 2004;110:568-571.
-



World Health Organization Consultation of Obesity.

Obesity: preventing and managing the global epidemic: Division of Noncommunicable Diseases, Program of Nutrition, Family and Reproductive Health.

Geneva, Switzerland: World Health Organization; 1998.

Yarnell J, McCrum E, Rumley A, et al.

Association of European population levels of thrombotic and inflammatory factors with risk of coronary heart disease: the MONICA Optional Haemostasis Study.

Eur Heart J. 2005;26:332-342.

Yarnell J, Patterson CC, Sweetnam PM, et al.

Haemostatic/ inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies.

Eur Heart J. 2004;25:1049-1056.

Yusuf S, Hawken S, Ôunpuu S et al.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study.

Lancet. 2004;364:937-952.

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in English. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text.
As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All **illustrations should be cited** in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text.
The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International** (SI) units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg*. 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation*. 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher’s editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author’s responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

LEAD ARTICLE

The lead article should not exceed 30 standard typed pages (7000 to 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of **“10 references of seminal papers”** as well as a separate list of **“100 Key References”** should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 15 standard typed pages (3000 to 4000 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

FASCINOMA CARDIOLOGICA ARTICLES

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.